This approach may prove beneficial for investigating the potential advantages of new ADCs in the context of HER2-ultra low BC (defined as a score of 0 with incomplete and faint staining in  >0 and ≤ 10% of tumor cells) in forthcoming studies [61]. This evidence concerns the gene ERBB2 and breast cancer.